<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04819217</url>
  </required_header>
  <id_info>
    <org_study_id>202002030RINA</org_study_id>
    <nct_id>NCT04819217</nct_id>
  </id_info>
  <brief_title>Study of Oral Uremic Toxin Absorbent and Probiotics to Retard the Progression of Chronic Kidney Disease</brief_title>
  <official_title>Study of Oral Uremic Toxin Absorbent and Probiotics to Retard the Progression of Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with chronic kidney disease (CKD), uremic toxins accumulate when kidney function&#xD;
      declines. Those uremic toxins had a greater affinity to circulating proteins are called&#xD;
      &quot;protein bound uremic toxins, PBUT.&quot; Apart from traditional small or middle molecule uremic&#xD;
      toxins, the PBUTs can be rarely eliminated using traditional renal replacement therapy, even&#xD;
      using high flux dialysis modalities. Among these molecules identified, indoxyl sulfate (IS),&#xD;
      and p-cresol (PC) are mostly studied. Both in vitro and in vivo study, IS and PC are&#xD;
      associated with endothelial dysfunction, vascular smooth muscle proliferation, and increased&#xD;
      risk for CV outcomes.&#xD;
&#xD;
      The uremic toxins (IS and PC) are originated in the endogenous environment, mainly from the&#xD;
      protein metabolism, food intake, or produced by gut microbiota. Prevention of IS or PC&#xD;
      precursors from being absorbed across the intestinal tract has been extensively studied in&#xD;
      the renal literature by use of oral adsorbents. In animal models, activated charcoal reduces&#xD;
      the serum concentration of creatinine (cre) and may delay CKD progression by alleviating IS&#xD;
      overload. An oral form of non-absorbable surface-modified activated bamboo charcoal (ABC),&#xD;
      has been demonstrated to effectively reduce circulating and renal IS levels in animal models.&#xD;
&#xD;
      Recently, probiotics, prebiotics or synbiotics have been reported to reduce inflammation,&#xD;
      improve kidney function and retard progression of CKD by restoring the symbiosis of gut&#xD;
      microflora in patients with CKD. A randomized trial found synbiotics decreased serum PCS&#xD;
      without reducing serum IS in non-dialysis CKD. Another study found that synbiotics delayed&#xD;
      CKD progression. A systematic review found prebiotic and probiotic therapies reduced IS and&#xD;
      PCS in patients with end stage kidney disease (ESKD) on haemodialysis. However, it is unclear&#xD;
      whether the results hold true for other patients with CKD. Based on these previous findings,&#xD;
      investigators will conduct a prospective randomized open blinded end-point (PROBE) study to&#xD;
      see if oral uremic toxin absorbent + probiotics prevent CKD progression. Also, a panel of&#xD;
      clinical and biochemical profiles will be checked to investigate possible link between&#xD;
      several biomarkers and clinical response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with chronic kidney disease (CKD), uremic toxins accumulate when kidney function&#xD;
      declines. Those uremic toxins had a greater affinity to circulating proteins are called&#xD;
      &quot;protein bound uremic toxins, PBUT.&quot; Apart from traditional small or middle molecule uremic&#xD;
      toxins, the PBUTs can be rarely eliminated using traditional renal replacement therapy, even&#xD;
      using high flux dialysis modalities. Among these molecules identified, indoxyl sulfate (IS),&#xD;
      and p-cresol (PC) are mostly studied. Both in vitro and in vivo study, IS and PC are&#xD;
      associated with endothelial dysfunction, vascular smooth muscle proliferation, and increased&#xD;
      risk for CV outcomes.&#xD;
&#xD;
      The uremic toxins (IS and PC) are originated in the endogenous environment, mainly from the&#xD;
      protein metabolism, food intake, or produced by gut microbiota. Prevention of IS or PC&#xD;
      precursors from being absorbed across the intestinal tract has been extensively studied in&#xD;
      the renal literature by use of oral adsorbents. In animal models, activated charcoal reduces&#xD;
      the serum concentration of creatinine (cre) and may delay CKD progression by alleviating IS&#xD;
      overload. An oral form of non-absorbable surface-modified activated bamboo charcoal (ABC),&#xD;
      has been demonstrated to effectively reduce circulating and renal IS levels in animal models.&#xD;
&#xD;
      Recently, probiotics, prebiotics or synbiotics have been reported to reduce inflammation,&#xD;
      improve kidney function and retard progression of CKD by restoring the symbiosis of gut&#xD;
      microflora in patients with CKD. A randomized trial found synbiotics decreased serum PCS&#xD;
      without reducing serum IS in non-dialysis CKD. Another study found that synbiotics delayed&#xD;
      CKD progression. A systematic review found prebiotic and probiotic therapies reduced IS and&#xD;
      PCS in patients with end stage kidney disease (ESKD) on haemodialysis. However, it is unclear&#xD;
      whether the results hold true for other patients with CKD. Based on these previous findings,&#xD;
      investigators will conduct a prospective randomized open blinded end-point (PROBE) study to&#xD;
      see if oral uremic toxin absorbent + probiotics prevent CKD progression. Also, a panel of&#xD;
      clinical and biochemical profiles will be checked to investigate possible link between&#xD;
      several biomarkers and clinical response.&#xD;
&#xD;
      During this 6 months' trial, eligible 120 patients with eGFR 15 &lt; eGFR &lt; 45 ml/min/1.73m2 and&#xD;
      UACR &gt; 100 mg/g will be enrolled and randomized into 4 groups. The patients in group 1 will&#xD;
      receive CharXenPlus 4g (with ABC 2g) thrice daily + CharXprob 0.8 g once daily in the initial&#xD;
      3 months. Group 2 will receive CharXenPlus 4g thrice daily in the initial 3 months, and&#xD;
      CharXprob 0.8 g once daily in the last 3 months. Group 3 will receive CharXprob 0.8 g once&#xD;
      daily in the initial 3 months, and CharXenPlus 4g thrice daily in the last 3 months. Group 4&#xD;
      will only receive CharXprob 0.8 g once daily in the last 3 months. In addition to demographic&#xD;
      data, the degrees of proteinuria (UACR), serum albumin, AST, ALT, BUN, creatinine, Na, K, Cl,&#xD;
      Ca, P, Mg, uric acid, IS, PC, TMAO, FGF-23, klotho, KIM-1, NGAL, metabolomics, lcnRNA, and&#xD;
      fecal microbiota will be assessed at the baseline, 3rd and 6th month of the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The % change of UACR</measure>
    <time_frame>baseline, 3rd month, 6th month</time_frame>
    <description>Urine albumin divided by urine creatinine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The % change of Creatinine</measure>
    <time_frame>baseline, 3rd month, 6th month</time_frame>
    <description>Serum creatinine (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The % change of eGFR</measure>
    <time_frame>baseline, 3rd month, 6th month</time_frame>
    <description>Estimates glomerular filtration rate based on creatinine and patient characteristics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FGF-23</measure>
    <time_frame>baseline, 3rd month, 6th month</time_frame>
    <description>protein-binding uremic toxin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma lncRNA</measure>
    <time_frame>baseline, 3rd month, 6th month</time_frame>
    <description>Long non-coding RNAs (long ncRNAs, lncRNA) are a type of RNA, defined as being transcripts with lengths exceeding 200 nucleotides that are not translated into protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiota</measure>
    <time_frame>baseline, 3rd month, 6th month</time_frame>
    <description>microorganism in fecese</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>CKD</condition>
  <arm_group>
    <arm_group_label>Active bamboo charcoal</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Based on these previous findings, we will conduct a prospective randomized open blinded end-point (PROBE) study to see if oral uremic toxin absorbent + probiotics prevent CKD progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Based on these previous findings, we will conduct a prospective randomized open blinded end-point (PROBE) study to see if oral uremic toxin absorbent + probiotics prevent CKD progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Active bamboo charcoal</intervention_name>
    <description>During this 6 months' trial, eligible 120 patients with eGFR 15 &lt; eGFR &lt; 45 ml/min/1.73m2 and UACR &gt; 100 mg/g will be enrolled and randomized into 4 groups. The patients in group 1 will receive CharXenPlus 4g (with ABC 2g) thrice daily + CharXprob 0.8 g once daily in the initial 3 months. Group 2 will receive CharXenPlus 4g thrice daily in the initial 3 months, and CharXprob 0.8 g once daily in the last 3 months. Group 3 will receive CharXprob 0.8 g once daily in the initial 3 months, and CharXenPlus 4g thrice daily in the last 3 months. Group 4 will only receive CharXprob 0.8 g once daily in the last 3 months.</description>
    <arm_group_label>Active bamboo charcoal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>Probiotics</description>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 20 years old on the day of screening.&#xD;
&#xD;
          2. CKD patients with eGFR 15 &lt; eGFR &lt;45 ml/min/1.73m2 and UACR &gt; 100 mg/g in a stable&#xD;
             status, creatinine elevated less than 0.3 mg/dL in at least 30 days before enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Baseline estimated glomerular filtration rates (eGFR) &lt; 15 ml/min/1.73m2 according to&#xD;
             MDRD equation.&#xD;
&#xD;
          2. Patients in severe malnutrition status, albumin less than 2.0 g/dL&#xD;
&#xD;
          3. Patients in severe anemia or active gastrointestinal bleeding with hemoglobulin &lt; 8&#xD;
             g/dL.&#xD;
&#xD;
          4. Peptic ulcer, esophageal varices, ileus or under fasting status&#xD;
&#xD;
          5. Previous gastrointestinal operation.&#xD;
&#xD;
          6. Chronic constipation, as defined with less than 3 bowel movements per week, straining,&#xD;
             hard stools, incomplete evacuation and inability to pass stool. If usage of oral&#xD;
             laxatives can achieve bowel movement, this patient will not be excluded.&#xD;
&#xD;
          7. Patients with major hemorrhage, as defined with acute hemorrhage and requirement of&#xD;
             blood transfusion during index admission.&#xD;
&#xD;
          8. Patients with a biopsy proved or clinically diagnosed advanced liver cirrhosis, Child&#xD;
             classification B or C.&#xD;
&#xD;
          9. Solid organ or hematological transplantation recipients.&#xD;
&#xD;
         10. Patients with oliguric kidney injury, as defined with less than 500 cc/day.&#xD;
&#xD;
         11. Evidence of obstructive kidney injury or polycystic kidney disease.&#xD;
&#xD;
         12. Antibiotics or probiotics treatment within the last 2 weeks before enrollment and&#xD;
             during follow-up period.&#xD;
&#xD;
         13. Presence or history of malignant neoplasms within the past 5 years prior to the day of&#xD;
             screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chau chung Wu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chau chung Wu, Ph.D.</last_name>
    <phone>02-23123456</phone>
    <phone_ext>88560</phone_ext>
    <email>Chauchungwu@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mei-Chang Huang, Master</last_name>
    <phone>02-23123456</phone>
    <phone_ext>88559</phone_ext>
    <email>r204.cc01@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NTUH</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chau chung Wu, PhD</last_name>
      <phone>02-23123456</phone>
      <phone_ext>88560</phone_ext>
      <email>Chauchungwu@ntu.edu.tw</email>
    </contact>
    <contact_backup>
      <last_name>Mei-Chen Huang, master</last_name>
      <phone>02-23123456</phone>
      <phone_ext>885589</phone_ext>
      <email>r204.cc01@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD oral absorbent probiotics LncRNA, gut microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

